Patents by Inventor Karen Jane Meyrick Morrison

Karen Jane Meyrick Morrison has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES THAT BIND TO AXL PROTEINS
    Publication number: 20240117055
    Abstract: Antibodies that bind to AXL protein and variants thereof are described herein. AXL exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the MAbs of the invention provide a diagnostic composition for the treatment and management of cancer.
    Type: Application
    Filed: June 29, 2023
    Publication date: April 11, 2024
    Applicant: AGENSYS, INC.
    Inventor: Karen Jane Meyrick MORRISON
  • ANTIBODIES THAT BIND TO AXL PROTEINS
    Publication number: 20240076390
    Abstract: Antibodies that bind to AXL protein and variants thereof are described herein. AXL exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the MAbs of the invention provide a diagnostic composition for the treatment and management of cancer.
    Type: Application
    Filed: June 29, 2023
    Publication date: March 7, 2024
    Applicant: AGENSYS, INC.
    Inventor: Karen Jane Meyrick MORRISON
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS
    Publication number: 20240043556
    Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: March 10, 2023
    Publication date: February 8, 2024
    Applicants: AGENSYS, INC., SEAGEN INC.
    Inventors: Robert Kendall MORRISON, Zili AN, Karen Jane Meyrick MORRISON, Josh SNYDER, Xiao-Chi JIA
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS
    Publication number: 20230346968
    Abstract: Antibody drug conjugates (ADC’s) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC’s of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: December 14, 2022
    Publication date: November 2, 2023
    Applicants: AGENSYS, INC., SEAGEN INC.
    Inventors: Daulet SATPAYEV, Robert Kendall MORRISON, Karen Jane Meyrick MORRISON, Jean GUDAS, Aya JAKOBOVITS, Michael TORGOV, Zili AN
  • Antibodies that bind to AXL proteins
    Patent number: 11739155
    Abstract: Antibodies that bind to AXL protein and variants thereof are described herein. AXL exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the MAbs of the invention provide a diagnostic composition for the treatment and management of cancer.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: August 29, 2023
    Assignee: AGENSYS, INC.
    Inventor: Karen Jane Meyrick Morrison
  • Antibodies that bind to AXL proteins
    Patent number: 11718677
    Abstract: Antibodies that bind to AXL protein and variants thereof are described herein. AXL exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the MAbs of the invention provide a diagnostic composition for the treatment and management of cancer.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: August 8, 2023
    Assignee: AGENSYS, INC.
    Inventor: Karen Jane Meyrick Morrison
  • Antibody drug conjugates (ADC) that bind to 158P1D7 proteins
    Patent number: 11634503
    Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: April 25, 2023
    Assignees: AGENSYS, INC., SEAGEN INC.
    Inventors: Robert Kendall Morrison, Zili An, Karen Jane Meyrick Morrison, Josh Snyder, Xiao-Chi Jia
  • Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
    Patent number: 11559582
    Abstract: Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: January 24, 2023
    Assignees: AGENSYS, INC., SEAGEN INC.
    Inventors: Daulet Satpayev, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Jean Gudas, Aya Jakobovits, Michael Torgov, Zili An
  • Nectin-4 binding proteins and methods of use thereof
    Patent number: 11292837
    Abstract: Provided herein are compositions, methods and uses involving antibodies that specifically bind to Nectin-4. Also provided herein are methods for assessing Nectin-4 expression in a sample or a patient and methods for assessing responsiveness of a cancer patient to an anti-cancer therapeutic agent.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: April 5, 2022
    Assignee: AGENSYS, INC.
    Inventors: Karen Jane Meyrick Morrison, Fernando Donate, Peng Yang
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS
    Publication number: 20210283268
    Abstract: Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: December 15, 2020
    Publication date: September 16, 2021
    Applicants: AGENSYS, INC., SEAGEN INC.
    Inventors: Daulet SATPAYEV, Robert Kendall MORRISON, Karen Jane Meyrick MORRISON, Jean GUDAS, Aya JAKOBOVITS, Michael TORGOV, Zili AN
  • ANTIBODIES THAT BIND TO AXL PROTEINS
    Publication number: 20210188985
    Abstract: Antibodies that bind to AXL protein and variants thereof are described herein. AXL exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the MAbs of the invention provide a diagnostic composition for the treatment and management of cancer.
    Type: Application
    Filed: August 6, 2020
    Publication date: June 24, 2021
    Applicant: AGENSYS, INC.
    Inventor: Karen Jane Meyrick MORRISON
  • ANTIBODIES THAT BIND TO AXL PROTEINS
    Publication number: 20210188984
    Abstract: Antibodies that bind to AXL protein and variants thereof are described herein. AXL exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the MAbs of the invention provide a diagnostic composition for the treatment and management of cancer.
    Type: Application
    Filed: August 6, 2020
    Publication date: June 24, 2021
    Applicant: AGENSYS, INC.
    Inventor: Karen Jane Meyrick MORRISON
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS
    Publication number: 20210095043
    Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: May 4, 2020
    Publication date: April 1, 2021
    Applicants: AGENSYS, INC., SEAGEN INC.
    Inventors: Robert Kendall MORRISON, Zili AN, Karen Jane Meyrick MORRISON, Josh SNYDER, Xiao-Chi JIA
  • Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
    Patent number: 10894090
    Abstract: Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: January 19, 2021
    Assignees: AGENSYS, INC., SEAGEN INC.
    Inventors: Daulet Satpayev, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Jean Gudas, Aya Jakobovits, Michael Torgov, Zili An
  • Antibodies that bind to AXL proteins
    Patent number: 10787517
    Abstract: Antibodies that bind to AXL protein and variants thereof are described herein. AXL exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the MAbs of the invention provide a diagnostic composition for the treatment and management of cancer.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: September 29, 2020
    Assignee: AGENSYS, INC.
    Inventor: Karen Jane Meyrick Morrison
  • Antibodies that bind to AXL proteins
    Patent number: 10787516
    Abstract: Antibodies that bind to AXL protein and variants thereof are described herein. AXL exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the MAbs of the invention provide a diagnostic composition for the treatment and management of cancer.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: September 29, 2020
    Assignee: AGENSYS, INC.
    Inventor: Karen Jane Meyrick Morrison
  • NECTIN-4 BINDING PROTEINS AND METHODS OF USE THEREOF
    Publication number: 20200231670
    Abstract: Provided herein are compositions, methods and uses involving antibodies that specifically bind to Nectin-4. Also provided herein are methods for assessing Nectin-4 expression in a sample or a patient and methods for assessing responsiveness of a cancer patient to an anti-cancer therapeutic agent.
    Type: Application
    Filed: June 4, 2018
    Publication date: July 23, 2020
    Applicant: AGENSYS, INC.
    Inventors: Karen Jane Meyrick MORRISON, Fernando DONATE, Peng YANG
  • Antibody drug conjugates (ADC) that bind to 158P1D7 proteins
    Patent number: 10669348
    Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: June 2, 2020
    Assignees: AGENSYS, INC., SEATTLE GENETICS, INC.
    Inventors: Robert Kendall Morrison, Zili An, Karen Jane Meyrick Morrison, Josh Snyder, Xiao-Chi Jia
  • NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER
    Publication number: 20190092874
    Abstract: A novel gene 0161P2F10B (also designated 161P2F10B) and its encoded protein, and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.
    Type: Application
    Filed: March 16, 2018
    Publication date: March 28, 2019
    Inventors: Aya JAKOBOVITS, Arthur B. RAITANO, Mary FARIS, Rene S. HUBERT, Wangmao GE, Karen Jane Meyrick MORRISON, Robert Kendall MORRISON, Pia M. CHALLITA-EID
  • Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
    Patent number: RE48389
    Abstract: Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: January 12, 2021
    Assignees: AGENSYS, INC., SEAGEN INC.
    Inventors: Daulet Satpayev, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Jean Gudas, Aya Jakobovits, Michael Torgov, Zili An